Positive response to neoadjuvant cyclophosphamide and doxorubicin in topoisomerase II nonamplified/HER2/neu negative/polysomy 17 absent breast cancer patients

PURPOSE: Human epidermal growth factor receptor 2 (HER2)/neu, topoisomerase II alpha (TOP2A), and polysomy 17 may predict tumor responsiveness to doxorubicin (DOX) therapy. METHODS: We identified neoadjuvant DOX/cyclophosphamide treated breast cancer patients in our registry from 1997 to 2008 with s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaplan, Henry G, Malmgren, Judith A, Atwood, Mary, Goldstein, Lynn C
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004590/
https://www.ncbi.nlm.nih.gov/pubmed/21188112
http://dx.doi.org/10.2147/CMR.S12849

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004590/
https://www.ncbi.nlm.nih.gov/pubmed/21188112
http://dx.doi.org/10.2147/CMR.S12849

Ejemplares similares